Fundraising Fox
Ncardia
Founded 2011 · 42 employees on LinkedIn · 3 known investors
Find your way into Ncardia
372 people in our graph can introduce you to the Ncardia team.
Sign up to see every warm intro you have to Ncardia
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ncardia team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Ncardia develops induced pluripotent stem cell (iPSC) technologies and services for drug discovery, safety testing, and regenerative medicine applications. The company serves pharmaceutical and biotech organizations seeking advanced cellular models to accelerate therapeutic development and validate drug candidates.
Founders & leadership
Ncardia was founded in 2011 by Stefan Braam, Prof. Dr. Mummery, and Prof. Dr. Passier.
SB
Stefan BraamCo-founder & Chief Technical OfficerStefan Braam holds an MSc and PhD in stem cell biology and has founded and led Ncardia, serving as CEO and co-founder where he was a key inventor of the core iPSC technologies. He has worked as a researcher in the UK and Australia, and holds multiple patents in stem cell technology.
PD
Prof. Dr. Mummery
PD
Prof. Dr. Passier
HS
Herman Spolders
JD
Jeroen de GrootChief Operation Officer Early DiscoveryJeroen de Groot holds a Master's degree in Biology from the University of Leiden (1996) and a Ph.D. from Utrecht University Medical Center (2001). He brings extensive experience in life science operations, R&D strategy, and team leadership across drug discovery, preclinical development, and business management roles.
Investors · 3
Also in the syndicate · 1
Kiniciti
Founder mafia
2 people who came through Ncardia went on to found or lead other companies.
Frequently asked questions
- What does Ncardia do?
- Ncardia develops induced pluripotent stem cell (iPSC) technologies and services for drug discovery, safety testing, and regenerative medicine applications. The company serves pharmaceutical and biotech organizations seeking advanced cellular models to accelerate therapeutic development and validate drug candidates.
- Who founded Ncardia?
- Ncardia was founded by Stefan Braam, Prof. Dr. Mummery, Prof. Dr. Passier in 2011.
- Who are Ncardia's investors?
- Ncardia's investors include Épimède, Vesalius Biocapital Partners.